Our Ref: 105
February 2026

Doncaster and Bassetlaw Teaching Hospitals
NHS Foundation Trust

Freedom of Information Act Request

I am writing to request information under the Freedom of Information Act 2000.

A. How many patients have been treated with the following drugs in the past 4 months:

- Atogepant (Aquipta) – any disease - 0
- Erenumab (Aimovig) - any disease - 0
- Eptinezumab (Vyepti) – any disease - 0
- Fremanezumab (Ajovy) - any disease - 0
- Galcanezumab (Emgality) - any disease - 0
- Rimegepant (Vydura) – any disease - 7
- Botulinum Toxin (i.e., Botox, Dysport, Xeomin) - migraine ONLY – see below

B. How many patients have you treated in the last 4 months for acute migraine with:
Rimegepant (Vydura)

DBTH holds the information on the subject you have requested. However, I advise you that we will not be able to answer your request without exceeding the appropriate limit. This is because our pharmacy system doesn't store diagnosis data, so we're unable to determine this against the prescribed treatment. To ascertain this data, the Trust would need to perform an audit of each individual patient record, which wouldn't be achievable within the s.12 timescale of the Freedom of Information Act 2000.

. Section 12 of the Act makes provision for public authorities to refuse requests for information where the cost of dealing with them would exceed the appropriate limit, We have estimated that it would take more than 18 hours to carry out a manual search to locate, retrieve, and extract all the information you have requested. In this situation the associated cost would therefore exceed the appropriate fee limit of £450 set out under Freedom of Information & Data Protection (Appropriate Limit and Fees) Regulations 2007.

The fee limit specified in regulations for NHS trusts represents the cost of one person spending 2½ working days at a rate of £25 per hour determining whether the Trust holds the information sought and then locating, retrieving and extracting that information.

C. Does the trust actively initiate a treatment pause (usually at 12 months) of anti-CGRP (calcitonin gene-related peptide inhibitors) migraine treatment with the aim to re-start treatment if the patient continues to fit the criteria (Yes/No)?

Yes.

Our Ref: 105
February 2026

Doncaster and Bassetlaw Teaching Hospitals
NHS Foundation Trust

Doncaster and Bassetlaw Teaching Hospitals NHS Foundation Trust follows relevant national guidance and commissioning criteria for anti-CGRP migraine treatments. In line with these requirements, patients are typically reviewed after 12 months of treatment, and a treatment pause may be initiated where clinically appropriate to assess ongoing response and continued eligibility. Treatment may be restarted if the patient continues to meet the agreed criteria.

If you are not satisfied with the handling of your request, you have the right to request an internal review. Requests for an internal review should be submitted within 40 working days from the date of this response, and should be addressed to d.wraith@nhs.net.

If you remain dissatisfied after the internal review, you have the right to appeal to the Information Commissioner's Office (ICO). The ICO can be contacted at:

Information Commissioner's Office
Wycliffe House
Water Lane
Wilmslow
Cheshire
SK9 5AF
Tel: 0303 123 1113
Website: https://ico.org.uk/make-a-complaint/

Our Ref: 105
February 2026

Doncaster and Bassetlaw Teaching Hospitals
NHS Foundation Trust